In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days.
BACKGROUND
The Mirasol pathogen reduction technology system is known to increase the activation and metabolic rate of platelets (PLTs). Storage of Mirasol PLTs in PLT storage medium (PSM) has the potential to slow this accelerated PLT storage lesion. We investigated the quality of Mirasol-treated PLTs stored in either 50% SSP+ or 50% Composol for 8 days.


METHODS
Single-donor double hyperconcentrates were divided between control and Mirasol-treated arms and after treatment were suspended in approximately 50% (vol/vol) SSP+ (n = 8) or Composol (n = 7). In vitro markers of PLT activation and/or apoptosis were measured over an 8-day storage period.


RESULTS
Mirasol treatment resulted in increased spontaneous PLT activation and glycolysis and these effects were worsened when PLTs were treated below a certain volume (150 mL). At higher treatment volumes there were no significant differences between treated units stored in either Composol or SSP+. When low-volume units were stored in Composol the median pH fell below 6.4 on Day 5 and bicarbonate was undetectable, whereas in SSP+ the median pH value was greater than 6.9 and bicarbonate remained at detectable levels, despite other markers of in vitro function being similar to those of Composol.


CONCLUSIONS
Mirasol treatment of PLTs followed by storage in PSM results in increased PLT activation and metabolism to a level similar to that reported for PLTs treated and stored in plasma. Units treated at a low volume (<150 mL) showed poor in vitro quality.
Components Development Laboratory, NHS Blood & Transplant, Brentwood, UK. phil.cookson@nhsbt.nhs.uk.
Philip
P
Cookson
Stephen
S
Thomas
Susanne
S
Marschner
Ray
R
Goodrich
Rebecca
R
Cardigan
D000255:Adenosine Triphosphate / Q000097:blood; D017209:Apoptosis; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D001793:Blood Preservation / Q000379:methods*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D015539:Platelet Activation; D017713:Platelet Transfusion; D012256:Riboflavin / Q000494:pharmacology*; D013997:Time Factors; D014466:Ultraviolet Rays
D000255:Adenosine Triphosphate; D012256:Riboflavin